[
Berghea, F., Berghea, C. E., Zaharia, D., Trandafir, A. I., Nita, E. C., Vlad, V. M. (2021). Residual pain in the context of selecting and switching biologic therapy in inflammatory rheumatic diseases. Front. Med. (Lausanne), 8, 712645. DOI: 10.3389/fmed.2021.712645.10.3389/fmed.2021.712645841582634485342
]Search in Google Scholar
[
Black, R. J., Lester, S., Buchbinder, R., Barrett, C., Lassere, M., March, L., Whittle, S., Hill, C. L. (2017). Factors associated with oral glucocorticoid use in patients with rheumatoid arthritis: A drug use study from a prospective national biologics registry. Arthritis Res. Ther., 19 (1), 253.10.1186/s13075-017-1461-3568872429141677
]Search in Google Scholar
[
Bos, W. H., van Tubergen, A., Vonkeman, H. E. (2021). Telemedicine for patients with rheumatic and musculoskeletal diseases during the COVID-19 pandemic; a positive experience in the Netherlands. Rheumatol. Int., 41 (3), 565–573.10.1007/s00296-020-04771-6780963833449162
]Search in Google Scholar
[
D’Angelo, S., Carriero, A., Gilio, M., Ursini, F., Leccese, P., Palazzi, C. (2018). Safety of treatment options for spondyloarthritis: A narrative review. Expert Opin. Drug Saf., 17 (5), 475–486.10.1080/14740338.2018.144878529505325
]Search in Google Scholar
[
Dawson, J. K., Quah, E., Earnshaw, B., Amoasii, C., Mudawi, T., Spencer, L. G. (2021). Does methotrexate cause progressive fibrotic interstitial lung disease? A systematic review. Rheumatol. Int., 41, 1055–1064.10.1007/s00296-020-04773-4807928933515067
]Search in Google Scholar
[
Ducourau, E., Rispens, T., Samain, M., Dernis, E., Le Guilchard, F., Andras, L., Perdriger, A., Lespessailles, E., Martin, A., Cormier, G., et al. (2020). Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: A multicentric randomised trial. RMD Open, 6 (1), e001047. DOI: 10.1136/rmdopen-2019-001047.10.1136/rmdopen-2019-001047704695431958280
]Search in Google Scholar
[
Filipowicz-Sosnowska, A. (2019). Comorbidities and multimorbidity in rheumatic diseases. Reumatologia, 57 (1), 1–2.10.5114/reum.2019.83232640982730858624
]Search in Google Scholar
[
Gossec, L., Baraliakos, X., Kerschbaumer, A., de Wit, M., McInnes, I., Dougados, M., Primdahl, J., McGonagle, D. G., Aletaha, D., Balanescu, A., et al. (2020). EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann. Rheum. Dis., 79, 700–712.10.1136/annrheumdis-2020-217159728604832434812
]Search in Google Scholar
[
Hainer, R., O’Riordan, B. (2020). From virtual care to hybrid care: COVID-19 and the future of telehealth insights from the 2020 Amwell Physician and Consumer Survey. https://static.americanwell.com/app/uploads/2020/09/Amwell-2020-Physician-and-Consumer-Survey.pdf (accessed 13.06.2021).
]Search in Google Scholar
[
Hua, C., Buttgereit, F., Combe, B. (2020). Glucocorticoids in rheumatoid arthritis: Current status and future studies. RMD Open, 6 (1), e000536. DOI: 10.1136/rmdopen-2017-000536.10.1136/rmdopen-2017-000536704696831958273
]Search in Google Scholar
[
Hunter, T., Nguyen, C., Birt, J., Smith, J., Shan, M., Tan, H., Lisse, J., Isenberg, K. (2021). Pain medication and corticosteroid use in ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis in the United States: A retrospective observational sudy. Rheumatol. Ther., 8, 1371–1382.10.1007/s40744-021-00344-6838059534312825
]Search in Google Scholar
[
Isaacs, J. D., Burmester, G. R. (2020). Smart battles: Immunosuppression versus immunomodulation in the inflammatory RMDs. Ann. Rheum. Dis., 79 (8), 991–993.10.1136/annrheumdis-2020-218019739248232527869
]Search in Google Scholar
[
Jackson, L. E., Edgil, T. A., Hill, B., Owensby, J. K., Smith, C. H., Singh, J. A., Danila, M. I. (2022). Telemedicine in rheumatology care: A systematic review. Semin. Arthritis Rheum., 56, 152045. DOI: 10.1016/j.semarthrit.2022.152045.10.1016/j.semarthrit.2022.15204535843158
]Search in Google Scholar
[
Jokar, M., Jokar, M. (2018). Prevalence of inflammatory rheumatic diseases in a rheumatologic outpatient clinic: Analysis of 12626 cases. Rheumatol. Res., 3 (1), 21–27.10.22631/rr.2017.69997.1037
]Search in Google Scholar
[
Makol, A., Davis, J. M. 3rd, Crowson, C. S., Therneau, T. M., Gabriel S. E, Matteson, E. L. (2014). Time trends in glucocorticoid use in rheumatoid arthritis: Results from a population-based inception cohort, 1980–1994 versus 1995–2007. Arthritis Care Res., 66 (10), 1482–1488.10.1002/acr.22365417727924821680
]Search in Google Scholar
[
McInnes, I. B., Gravallese, E. M. (2021). Immune-mediated inflammatory disease therapeutics: past, present and future. Nat. Rev. Immunol., 13, 1–7.10.1038/s41577-021-00603-1843686734518662
]Search in Google Scholar
[
Mikuls, T. R., Johnson, S. R., Fraenkel, L., Arasaratnam, R. J., Baden, L. R., Bermas, B. L., Chatham, W., Cohen, S., Costenbader, K., Gravallese, E. M., et al. (2020). American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 1. Arthritis Rheumatol., 72 (8), 1241–1251.10.1002/art.4130132349183
]Search in Google Scholar
[
Myasoedova, E., Davis, J., Matteson, E. L., Crowson, C. S. (2020). Is the epidemiology of rheumatoid arthritis changing? Results from a population-based incidence study, 1985–2014. Ann. Rhem. Dis., 79 (4), 440–444.10.1136/annrheumdis-2019-216694708546432066556
]Search in Google Scholar
[
Piga, M., Floris, A., Congia, M., Chessa, E., Cangemi, I., Cauli, A. (2022). Telemedicine in rheumatology: high specificity and sensitivity of follow-up virtual video consultations during COVID-19 pandemic. Rheumatology (Oxford), 61 (5),1795–1801.10.1093/rheumatology/keab632843639334352098
]Search in Google Scholar
[
Radner, H. (2016). Multimorbidity in rheumatic conditions. Wien. Klin. Wochenschr., 128 (21–22), 786–790.10.1007/s00508-016-1090-x510480927738754
]Search in Google Scholar
[
Ruderman, E. M. (2012). Overview of safety of non-biologic and biologic DMARDs, Rheumatol., 51 (6), 37–43.
]Search in Google Scholar
[
Santos-Moreno, P., Chavez-Chavez, J., Hernández-Zambrano, S. M., Rivera-Triana, D. P., Castiblanco-Montañez, R. A., Aza, A., Buitrago-Garcia, D., Villarreal, L., Rojas-Villarraga, A. (2021). Experience of tele-medicine use in a big cohort of patients with rheumatoid arthritis during COVID-19 pandemic. Ann. Rheum. Dis., 80, e65. DOI: 10.1136/annrheumdis-2020-218165.10.1136/annrheumdis-2020-21816532586920
]Search in Google Scholar
[
Sathi, N., Chikura, B., Kaushik, V. V., Wiswell, R., Dawson, J. K. (2012). How common is methotrexate pneumonitis? A large prospective study investigates. Clin. Rheumatol., 31, 79–83.10.1007/s10067-011-1758-621638023
]Search in Google Scholar
[
Sepriano, A., Kerschbaumer, A., Smolen, J. S., van der Heijde, D., Dougados, M., van Vollenhoven, R., McInnes, I. B., Bijlsma, J. W., Burmester, G. R., de Wit, M., Falzon, L., Landewé, R. (2020). Safety of synthetic and biological DMARDs: A systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann. Rheum. Dis., 79 (6), 760–770.10.1136/annrheumdis-2019-21665332033941
]Search in Google Scholar
[
Smolen, J. S., Landewé, R. B. M., Bijlsma, J. W. J., Burmester, G. R., Dougados, M., Kerschbaumer, A., McInnes, I. B., Sepriano, A., van
]Search in Google Scholar
[
Vollenhoven, R. F., de Wit, M., et al. (2020). EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann. Rheum. Dis., 79 (6), 685–699.
]Search in Google Scholar
[
Sokka, T., Kautiainen, H., Toloza, S., Mäkinen, H., Verstappen, S. M., Lund Hetland, M., Naranjo, A., Baecklund, E., Herborn, G., Rau, R., et al. (2007). QUEST-RA: Quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries. Ann. Rheum. Dis., 66 (11), 1491–1496.10.1136/ard.2006.069252211161817412740
]Search in Google Scholar
[
Stouten, V., Pazmino, S., Verschueren, P., Mamouris, P., Westhovens, R., de Vlam, K., Bertrand, D., Van der Elst, K., Vaes, B., De Cock, D. (2021). Comorbidity burden in the first three years after diagnosis in patients with rheumatoid arthritis, psoriatic arthritis or spondyloarthritis: a general practice registry-based study. RMD Open, 7, e001671. DOI: 10.1136/rmdopen-2021-001671.10.1136/rmdopen-2021-001671822053434158353
]Search in Google Scholar
[
Tornero-Molina, J., Sánchez-Alonso, F., Fernández-Prada, M., Bris-Ochaita, M. L., Sifuentes-Giraldo, A., Vidal-Fuentes, J. (2021). Telerheumatology during the COVID-19 pandemic. Reumatol. Clin., 18 (3), 157–163. DOI: 10.1016/j.reumae.2020.10.002.10.1016/j.reumae.2020.10.002816932334088655
]Search in Google Scholar
[
Vanhoof, J., Declerck, K., Geusens, P. (2002). Prevalence of rheumatic diseases in a rheumatological outpatient practice. Ann. Rheum. Dis., 61, 453–455.10.1136/ard.61.5.453175408111959771
]Search in Google Scholar
[
Wiersinga, W. J., Rhodes, A., Cheng, A. C., Peacock, S. J., Prescott, H. C. (2020). Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): A review. JAMA, 324 (8), 782–793.10.1001/jama.2020.1283932648899
]Search in Google Scholar
[
Ziade, N., El Khoury, B., Zoghbi, M., Zoghbi, M., Merheb, G., Abi Karam, G., Mroue’, K., Messaykeh, J. (2020). Prevalence and pattern of comorbidities in chronic rheumatic and musculoskeletal diseases: The COMORD study. Sci. Rep., 10 (1), 7683. DOI:10.1038/s41598-020-64732-8.10.1038/s41598-020-64732-8720322832376850
]Search in Google Scholar
